Company Profile
Eli Lilly
— From injectable peptides to oral GLP-1 drugs, nucleic acids, and gene editing—with in-house manufacturing to match
Lilly and Company’s sales of $651 billion56% Mounjaro and Zepbound (both active ingredients are tilzepatide)Pharmaceutical Company In April 2026, after rapid growth with peptide drugs used in injectionsOral GLP-1 receptor actuator of low s not peptide(Foundayo, general name Orforgripron) has been approved in the United States. In addition, siRNA (nucleic acid medicine), gene editing, and technology (in vivo CAR-T) to create CAR-T cells in the body are acquired and developed in-house. 10 manufacturing locations in the United States In this article, the size of the company is concise,What to do with the modalities, and what to doFilter by
- In 30 seconds, you can see ly and DDS.
- About logo and company name
- Where is this company in the world of drug discovery and DDS?
- Company Size (Concise)
- Drug discovery and DDS resources
- Past Initiatives
- Future plans
- What is DDS?
- Collaboration mapping of drug discovery and DDS
- Technologies, Products and Services
- The risk of this company
- Glossary/Source/Ins ment and Source Response Table
1. Standing position in drug discovery and DDS
IndianapolisLilly Corporate Center
LowNucleic acid, genetic editing, ADC expansion
10sOriginal medicine 5 · Injectables and devices 4 · medicine 1
lyPharmaceutical CompanyHowever, it should be noted by drug discovery and DDS secretionwith both injection peptides and low s for the same target (GLP-1 receptor)Comment FactsHome In September 2026, the company explained 'Foundayo is a low molecular, not a peptide, and it is easy to scale because it can be manufactured with more established technology.' In other words, the company's strategy is not only how the drug works.Selection of "How to make large quantities"In its extension, he built a $65 billion original drug factory in Houston, Texas, in addition to OrforgripronOligonucleotide (nucleic acid)It was announced.
2. Logo and company name
E-Lily Japan Ltd. is a trademark of the company. In this article, we do not reproduce the generated image,
The logo (SVG) on the company’s official investor websiteHome img/eli_lilly_logo.svg Contact Us
Note: Corporate name Eli Lilly and Company"Lilly" is an abbreviation for our product release. In Japan, a subsidiary of NIPPON ELIILILE CO., LTD. conducts business, but this document is based on the disclosure of the U.S. headquarters. The product name (Mounjaro, Zepbound, Foundayo) and the general name (Cylzepatide, Orforgripron) are distinguished. In addition, the same active ingredient tilsepatide is sold in another product name called Zepbound for obesity such as Mounjaro and U.S. in diabetes.
Official Site:https://www.lilly.com/3. Where is this company in the world of drug discovery and DDS?
When you look at the modalities (types of medicine), the core of the current sales of e-Lily isPeptides(Cylzepatide) CloseLow(Orforgripron, low-cost drugs in the cancer area) andAntibodies(Dnanemab, Mikizumab, etc.) FactsHome In the development phase,siRNA(Repodisilane, Phase 3),Antibody Drug Complex (ADC)(Sophetabert Mipitekan, Phase 3), Therapy(I、-vec, Phase 3),Editing(VERVE-102) in vivo CAR-T(from Kelonia or Orna) and modalities are growing rapidly. The mechanism of each technology is handled by the technical commentary "peptide medicine and GLP-1", "nucleic acid medicine", "antibody medicine and ADC" and "CAR-T cells".
4. Company Scope (Concise)
Press only the scale of the company. All amounts are US dollars (million dollars), and the calendar year Facts。
| Index | FY2024 | FY2025 | January to June 2026 |
|---|---|---|---|
| Sales (US$ million) | 45,043 | 65,179 | 42,773 |
| Mounjaro (US$ million) | 11,540 | 22,965 | 18,605 |
| Zepbound (US$ million) | 4,926 | 13,542 | 9,088 |
| R&D expenses (US$ million) | 10,991 | 13,337 | 7,329 |
| Exp s for acquired products (acquired IPR & D, US$ million) | 3,280 | 2,910 | about 3,400 |
| Capital investment (acquiring tangible fixed assets, US$ million) | 5,058 | 7,841 | 5,259 |
| Year-end | ― | Approx. 50,000 | ― |
Mounjaro and Zepbound sales of 202556％January to June, 202665％The company itself discloses when accounting for FactsHome R&D costs are approximately 20.5% of net sales and approximately 12.0% of capital investments. 2025The calculation of this paperHome On the other hand, the company costs R&DCannot be disclosed by project, preclinical, clinical, and disease areas10-K Accordingly, the investment amount of modalities such as "how much to nucleic acid drugs" and "how much to edit genes" isNot published Undetermined / Future。
5. Drug discovery and DDS resources
We will organize the four points to be seen as a procedure, whether it was confirmed by 10-K・10-Q・Official release.
| Resource Types | ||
|---|---|---|
| Research | Personnel engaged in research and development at the end of 2025Approx. 12,000(50,000 50,000 employees) Mainly in the U.S., our in-house facilities in Indiana and the lease bases in California, Massachusetts、 New York | Facts |
| Person (Manufacturing) | More than 600 people are expected to work in Houston’s new factory. US$12.5 million for human resource development support at local San Jasinto College | Facts |
| Gold (R&D) | R&D expenses US$13,337 million (2025). Non-disclosure by modalities | Facts |
| Gold (Manufacturing Equipment) | Capital investment US$7.8 billion (2025). In the near future, capital investment will be greatly increased. Production reengineering in USA$500 billionExplanation in the official release | Facts |
| Gold (ex) manufacturing contract) | If you do not purchase the specified amount in the manufacturing contract and material supply contract for development productsUp to $100 billion(up to 8 years) | Facts |
| External introduction and acquisition | The pharmaceutical company acquired Orforglipron from Chugai Pharmaceutical in 2018. It also acquired Verve, POINT, Kelonia, Orna, and Emergence. | Facts |
| Venture investment | Unpaid investment commitment to venture capital fundsApprox. $92 million(2025 year-end). Non-dis sure of investors | Facts |
| AI/ AIulation resources | [With NVIDIA's support, we built our own supercomputer with over 1,000 B300 GPUs. Launched "Lilly TuneLab" to provide external bio-data companies with AI models learned from their data] | Facts |
| Collaboration with universities and research institutions | 10-K is generally described as "cooperating with academic institutions such as universities" and does not include individual collaborative research destinations and amounts | Not confirmed |
| Public Funds | The receipt of government research grants and subsidies for drug discovery and DDS is not included in the primary document confirmed | Not confirmed |
6. Past Initiatives
| Time | Home | The meaning of drug discovery and DDS |
|---|---|---|
| Year 2018 | Discovered by ChugaiOrforgripronDevelopment and sales rights in all worlds | Oral delivery of a low-oral GLP-1 receptor activator from outside |
| August 2023 | Acquisition of assets such as Emergence Theutics (ADC targeting Nectin-4, preclinical) and sansanis (antibody) | Reinforcement of ADC products from outside |
| November 8, 2023 | FDAZepbound InjectionApproved by chronic weight management of obesity (US/new approval) | Peptides that act on two receptors of GIP and GLP-1 expand into obesity |
| December 2023 | Acquisition of POINT Biopharma | es research, development and manufacturing capabilities for radioactive drugs |
| May 2024 | Winsconsin’s manufacturing base for $925 million | Expanded production network for injections |
| March 30, 2025 | siRNAReposlanyAnnouncement of Phase 2 (ALPACA) Results | Phase 3 (ACCLAIM-Lp(a)) |
| July 25, 2025 | Verve TherapeuticsCompleted the acquisition of a net worth of $54 million + conditional consideration | For cardio diseasesEditingd VERVE-102, PCSK9 |
| September 9, 2025 | [AI Drug Platform] PlatformLilly TuneLabOpen | Provides external models learned with drug efficacy and safety data gained over $10 billion |
| October 28, 2025 | Announced to build the largest supercomputer owned by NVIDIA and pharmaceutical companies | Search, optimize and verify [manufacturing] and use them for digital twins of manufacturing |
| February 23, 2026 | FDA ZepboundKwikPenApproval (Label expansion) | One-month injection device |
| April 1, 2026 | FDAFoundayoApprove with obesity (US/new approval) | Oral GLP-1 receptor actuator of low s not peptide |
| March to June 2026 | Ventyx, Orna (ORN-252, in vivo CAR-T), Ajax (oral JAK2 in)tor), Centessa,KeloniaAcquisition and acquisition of KLN-1010 in vivo CAR-T | Entered two new modalities to create CAR-T cells in the body |
| September 21, 2026 | in Houston, Texas$65 billion original drug factoryContact Us | Low s such as Orforgripron,OrigonucleotidePlanning to manufacture |
Major clinical trials (foundation of approval and ongoing trials)
| Test name (NCT number) | Phase | Main evaluation items | Results published (comparison contrast/point) |
|---|---|---|---|
| ATTAIN-1（NCT05869903） | Phase 3. 3,127 adult with diabetes-free obesity or complications | Change rate from the baseline of weight at 72 weeks | Decrease average of 12.4% (Plasebo 0.9%) for those who continue to treat at the highest dose. 11.1% reduction in analysis without treatment co ity 72 weeks |
| SURMOUNT-1 | Phase 3. 2,539 adults with diabetes-free obesity | Changes in weight | Average 20.9% reduction at 72 weeks at tilzepatide 15 mg (procebo 3.1% reduction) |
| ALPACA | Phase 2. 320 adults with high Lp(a) | Lp(a) | The average of 60 to 180 days after administration is 93.9% from the baseline at 400mg of lipodisilane. Contrast |
| ACCLAIM-Lp(a)（NCT06292013） | Phase 3. Adults with high Lp(a) (17 17,300). March 2024 | Time to first occurrence of cardio death, myocardial infarction, brain infarction, emergency coronary reconstruction (MACE-4) | In progress (recr ment ends). Completed March 2029 Undetermined / Future |
The results are based on the official announcement of the company and the content of the ClinicalTrials.gov program. This article does not recommend a specific drug, but does not inferior to other drugs. Please contact your doctor for treatment.
7. Future plans
Aim to expand globallyOver 40 countries
Achieve key evaluation itemsObesity and type 2 diabetes. Application period is not disclosed
10-Q, as the main development progress after entering 2026, approval of Orforgripron and application with type 2 diabetes, Achieved the main evaluation item of obesity and type 2 diabetes in phase 3 of retortide, Phase 3 of erolarintide (e.g. obesity) and brainipatin (e.g. large depression), ADC Phase 3 in Platinum Sensitivity Ovarian Cancer FactsHome Both are expected to be approved Undetermined / Future Comment
None of the following documents have been listed Undetermined / Future。
modalities (peptides, low)s, nucleic acids, genes, in vivo CAR-T)R&D expenses/ Houston FactoryStart timeHomeProduction capacity/OrigonucleotideProducts/ RetortideApplication period/VERVE-102 and KLN-1010Next clinical phase and timeHome We do not adopt sales forecasts and market scale by media and survey companies.
8. What is this company aiming for drug discovery and DDS?
This includes parts that the company does not directly state.Calculation in the range that can be read from primary informationand write with the basis.
| Read | Primary Information | |
|---|---|---|
| GLP-1Not only injection peptides, but also low s that are easy to produceContact Us | "Low moleculars can be manufactured with more established technology, which is easy to scale" in Houston's construction release, and global expansion goals in 2027 | |
| Next"Long-lasting treatment" modalities(siRNA / gene editing) | Phase 2 design of the lipodisilane tested twice a year | |
| Cell therapy is not a method to culture cells outside the bodyHow to make CAR-T cells in the bodyContact Us | In vivo CAR-T, Kelonia and Orna acquired the acquisition and asset in 2026, and the acquisition of an in-house cultured CAR-T company has not been confirmed. | |
| Manufacturing capabilityand have a dedicated factory for each modalities | Publication of 10 bases in the U.S. to "Pharmaceu」s 5 · Injections and Devices 4 ·」tics 1" | Facts |
| AIIn addition to being used to explore our company, we also create relationships with external bio companies.Use | TuneLab adopts a mechanism that enables companies to use models to look back on providing learning data |
In the description of the Houston plant, the company is with OrforgripronOrigonucleotideHome Lebanon Advanced The)iesMedicine FactsHome On the other hand, the nucleic acid drug in Phase 3 in the 10-K pipeline table is lipodisilane (siRNA), and its large outcome test (ACCLAIM-Lp(a)) will be completed in March 2029. We have prepared the original nucleic acid production capacity at the stage before approval.and No Nucleic Acid DrugsOne of the pillars of future modalitiesThis article will read if it is positioned as Undetermined / Future。
9. Collaboration mapping of drug discovery and DDS
10. Technologies, Products and Services
| Technology | Typical Products and Initiatives | Stage |
|---|---|---|
| Peptides (injection) | Mounjaro Zepbound GIP and GLP-1 Development of retortardid and erolarincid | Approved/Phase 3 |
| Low) (oral GLP-1) | Foundayo. Low)s (non-peptide) taken once a day without diet or water) | Approved in the United States (April 1, 2026) |
| Nucleic acid drugs (siRNA) | Repurposing. Reduce production of Lp(a) component apo(a) | Phase 3 |
| Editing | VERVE-102 Acquisition of Verve | Under development (not confirmed in this article) |
| in vivo CAR-T | KLN-1010 (Kelonia), ORN-252 (Orna, CD19 targeted, autoimmune disease) | Phase 1 (ORN-252) |
| Antibody Drug Complex (ADC) | Sofetabert Mipitecan (targeted folate receptor α). FDA-determined treatment | Phase 3 |
| Therapy | I)-vec. Bioerum Biotechnologies | Phase 3 |
| Injection device | KwikPen (for Zepbound for 4 or 1 month), single vial 10-K is a part of its manufacturing process. | Sales |
| [AI Drug Service Service] | Lilly TuneLab Provides models learned from drug delivery, safety, and pre ical data to the outside by union learning | Published in September 2025 |
Even drugs aiming for the same GLP-1 receptor,Peptide InjectionHome[Low tablets]The material and process of manufacturing are completely different. The company said, "Low s can be manufactured with more established technology, and they are easy to scale."Production of original medicine by chemicalContact Us For human resource development, it is "Advanced chemical manufacturing" FactsHome Injectable side, it is possible to take 4 times in Zepbound.KwikPen10-K is a device manufacturing and assembly company. The pen type syringe is a component that directly connects the cartridges and rubber plugs to the management of proteins and peptides.
In the same Houston factoryOrigonucleotideIt is announced that it will be manufactured. Nucleic acid drugs are generally chemically synthesized by one base on solid-phase carriers, and are made with chemical modification and purification. This series of technical commentary "nucleic acid medicine", and the specific process of the company is not disclosed. [We share chemical facilities and human resources with low and nucleic acids].This is the characteristic of this factory that saw from the side of the material and process. Undetermined / Future。
11. Risks that this company has
| Risks | ||
|---|---|---|
| Focus on sales | 65% of sales from January to June 2026 came from Mounjaro and Zepbound. The company itself notes that fluctuations in the quantity of incremental drugs may have a significant impact on unfunding. | Facts |
| Price and insurance reimbursement | The U.S. government's drug price agreement (such as discounts for Medicare), government pricing controlled by inflation (Jardiance, 2028-Trulicity and Fresenius), | Facts |
| Excessive capital investment | If the demand is not read, the factory may be unnecessary, and the manufacturing contract may result in a payment obligation of up to $100 billion. | Facts |
| Development period of new modalities | "New modalities are more difficult to develop and may take longer." In vivo CAR-T | Facts |
| Failure of acquired products | The acquisition and development cost of $34 billion is calculated only from January to June 2026. The company clearly indicates that the candidate is not guaranteed to be a product | Facts |
| Drugs and counterfeit products | The distribution of counterfeit products and mass preparations of incletin drugs may damage safety and sales | Facts |
| Chinese dependence on supply network | Depends on China supplier as a whole industry. Impact of regulatory trends such as BIOSECURE Law | Facts |
| Low regulation makes manufacturing superior | Low。s are easy to produce and are easy to enter. Possibility to prevent entry barriers in the scale of peptide manufacturing |
12. Glossary
- Home
- Types and forms of medicine. It is divided into low。s, antibody, peptide, nucleic acid, cells, gene therapy, etc.
- GLP-1 receptor agonist
- Drugs that stimulate receptors of hormone GLP-1 insulin content and appetite. Used for diabetes and obesity.
- GIP
- A hormone that comes out of the intestine after eating the same as GLP-1. Cylzepatide acts on both GIP and GLP-1 receptors.
- Peptides
- Medi s with several to dozens of amino acids. It is easy to decompose by the stomach, and many are given in injection.
- Low-weight drugs
- Small chemical medicine with weight. It is easy to make tablets, and the manufacturing method is established.
- siRNA
- A nucleic acid drug that breaks down the design diagram (mRNA) of a specific protein with a short bi-stranded RNA.
- Origonucleotide
- A short chain of nucleic acids (bases) connected to dozens. The body of nucleic acid drugs such as siRNA and antis .
- in vivo CAR-T
- A method that directly identifies CAR (receptor to identify cancer cells) in the patient's body. No cell culture outside the body.
- ADC
- Antibody drug complex. Connect the drug to antibody with a linker and deliver the drug to targeted cells.
- API
- The active ingredient of the drug itself. Before processing to formulation (tablets, injections).
- acquired IPR&D
- The cost of the drug being acquired and introduced is calculated as a cost.
- Form 10-K／10-Q
- Annual reports and quarterly reports submitted by U.S. listed companies to SEC. with legal responsibility.
Concept diagram of AI generation13. Source
- Eli Lilly and Company Form 10-K for the year ended December 31, 2025 Business overview, product list, R&D system, personnel, manufacturing base, table, product sales, R&D costs, capital investment, manufacturing contract, venture investment, tie-up (Chugai Pharmaceutical, Boehringer Ingelheim factory), acquisition (Pfizer, POINT, Wisconsin Plant, asset acquisition), risk. https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm
- Eli Lilly and Company Form 10-Q for the quarterly period ended June 30, 2026 Acquisition of Kelonia, Centessa and Ventyx, acquisition of Orna and Ajax assets and development of assets from January to June 2026. https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm
- Eli Lilly and Company FDA approves Lilly's Foundayo (orforglipron)... (April 1, 2026). FDA approval, ATTAIN-1 result, low (non-peptide), introduced by Chugai Pharmaceutical. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill
- Eli Lilly and Company Copyright (C) 2019 )BISHI CO., LTD. All Rights Reserved. $65 billion original drug factory, production of oligonucleotides, breakdown of 10 bases in the United States, domestic production investment of $500 billion, human resource development with San Jacinto College, and global reach in 2027. https://investor.lilly.com/news-releases/news-release-details/lilly-breaks-ground-houston-one-ten-us-manufacturing-sites
- Eli Lilly and Company Lilly completes acquisition of Verve Theticseutics... Completion of Verve acquisition and position of genetic editing business. https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-verve-therapeutics-advance-one-time
- Eli Lilly and Company Lilly launches TuneLab platform The contents of the AI drug discovery platform and the mechanism of union learning. https://investor.lilly.com/news-releases/news-release-details/lilly-launches-tunelab-platform-give-biotechnology-companies
- Eli Lilly and Company NVIDIA to build the industry's most powerful AI supercomputer... (October 28, 2025) B300 GPU 1,000 supercomputers for search and manufacturing. https://investor.lilly.com/news-releases/news-release-details/lilly-partners-nvidia-build-industrys-most-powerful-ai
- Eli Lilly and Company Lilly's lepodisiran depression of ... lipoprotein(a)...(March 30, 2025). Being siRNA, phase 2 design and result of ALPACA. https://investor.lilly.com/news-releases/news-release-details/lillys-lepodisiran-reduced-levels-genetically-inherited-heart
- Eli Lilly and Company FDA Approves Lilly's Zepbound (FDAzepatide) for Management Weight Management... (November 8, 2023). FDA approval and GIP/GLP-1 action. https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight
- Eli Lilly and Company Zepbound (zezepatide) ... now available in multi-dose KwikPen (February 23, 2026). 4 times KwikPen label enlargement, result of SURMOUNT-1. https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-most-prescribed-weight-management
- ClinicalTrials.gov NCT06292013(ACCLAIM-Lp(a)) Phase 3 target, number of presumed registrations, major evaluation items, and schedule to be completed. https://clinicaltrials.gov/study/NCT06292013
- ClinicalTrials.gov NCT05869903 (ATTAIN-1). Phase 3 target, number of registrations, and major evaluation items. https://clinicaltrials.gov/study/NCT05869903
- Eli Lilly and Company Official website (for confirmation of company profile and logo) https://www.lilly.com/
14. Response table of claims and sources
| Content | ||
|---|---|---|
| Company name, year of establishment and corporateization, head office location, listed market | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm |
| Sales, product sales, R&D expenses, acquired IPR & D investment, about 50,000 employees and 12,000 R&D personnel | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm |
| Mounjaro and Zepbound 56% of sales in 2025 | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm |
| Net sales, product sales, R&D expenses, capital investment in January and June 2026, Mounjaro and Zepbound 65% | Facts | Source 2 https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm |
| R&D cost is about 20.5% of sales, about 12.0% of capital investment (2025) | The calculation of this paper | )ulation of this paper (cal)d from the number of source 1) https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm |
| Not to disclose R&D expenses by project | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm |
| The locations of production sites, new manufacturing sites, and device manufacturing with our own and third parties. | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm |
| Up to $100 billion payment obligations in the manufacturing contract, venture fund promises about $92 million | Facts | Source 1 https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm |
| Jardiance Partnership with Boehringer Ingel、 | Facts | Source 1・3 https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm |
| Acquisition of Verve POINT Wisconsin Plant and acquisition of assets such as Emergence and sansanis | Facts | Source 1・5 https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm |
| Acquisition of Kelonia・Centessa・Ventyx, acquisition of assets of Orna・Ajax and content of candidates | Facts | Source 2 https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm |
| Stages of development (repodisilane, sofetabert mipitecan, I -vec, retortardide, etc.). | Facts | Source 1・2 https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm |
| Foundayo’s U.S. approval (April 1, 2026), low), result of ATTAIN-1 | Facts | Source 3・12 https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-foundayotm-orforglipron-only-glp-1-pill |
| US$65 billion, US$5 billion, human resource development $12.5 million, and global expansion targets for 2027 | Facts | Source 4 https://investor.lilly.com/news-releases/news-release-details/lilly-breaks-ground-houston-one-ten-us-manufacturing-sites |
| TuneLab's content (data over $1 billion, union learning) | Facts | Source 6 https://investor.lilly.com/news-releases/news-release-details/lilly-launches-tunelab-platform-give-biotechnology-companies |
| Supercomputer construction with NVIDIA | Facts | Source 7 https://investor.lilly.com/news-releases/news-release-details/lilly-partners-nvidia-build-industrys-most-powerful-ai |
| The design and result of ALPACA that lipodisilane is siRNA | Facts | Source 8 https://investor.lilly.com/news-releases/news-release-details/lillys-lepodisiran-reduced-levels-genetically-inherited-heart |
| LALAIM-Lp(a) | Facts | Source11 https://clinicaltrials.gov/study/NCT06292013 |
| Zepbound’s U.S. approval (November 8, 2023) and GIP/GLP-1 action | Facts | Source 9 https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-zepboundtm-tirzepatide-chronic-weight |
| Approval of KwikPen for 4 times, result of SURMOUNT-1 | Facts | Source10 https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-most-prescribed-weight-management |
| Drug discovery and DDS classification (pharmaceu company / drug discovery biotech / contract development manufacturing and research) | The calculation of this paper | This article does not specify the company name. The company name is an example from the series of companies in this article. |
| Research and development costs by modalities, operating and production capacity of Houston plants, and application period for retortide | Undetermined / Future | None of the documents listed above. This article does not estimate https://www.sec.gov/Archives/edgar/data/59478/000005947826000081/lly-20260630.htm |
| Individual collaborative research with universities and receipt of public funds | Undetermined / Future | No individual description in Source 1. This article does not break even if it is not present https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm |
| An explanation that the particle of a pen-type syringe is involved in the management of absorption and dissolution, and a general explanation of the solid phase of nucleic acid. | Undetermined / Future | It is a general technical commentary, not disclosure of the company's process |
| In addition to injection peptides, it is read that even low- s that are easy to manufacture will take demand | Interpre of this paper from the description of the production of source 4 | |
| “Long-acting Treatment with One Treatment” Reads to Raise Modality in the Cardio Area. | Interpre of this article from the description of source 5 and 8 | |
| Cell therapy is read from the method of making CAR-T cells in the body | Interpre of this paper from the acquisition of Source 2 | |
| Read how to use AI to create relationships with external bio-entities | Interpre of this document from the mechanism of source 6 | |
| Reading that nucleic acid drugs are positioned as one of the future pillars, and reading that chemical facilities are shared with low s and nucleic acids. | Interpre of this paper from the factory planning and test schedule of Source 4 | |
| Risks of low molecularization. | Interpre of this article from the description of source 4 |
Last Updated:September 26, 2026/Troy Technical
All figures in this article are based on legal disclosure documents submitted by Euriri to the U.S. Securities and Exchange Commission (SEC), the official release of the company, and the ClinicalTrials.gov。 information. We do not use estimates and media-based numbers of survey companies. The "、ulation" section is an interpretation that the article reads from the primary information and is not an announcement of the company. This article is not medical advice, but is not recommended to use certain drugs.